TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02388932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study: NCT03200730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Dignity Intervention group
Description: A brief psychotherapeutic intervention offered to a family dyad (i.e., patient and one identified family caregiver) using narrative approach with life review elements. The purpose is to facilitate an open dialogue between the family dyad that strengthens family connectedness and emotional connection.
Study: NCT02529124

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PROTEIN
Description: The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PROTEIN
Description: The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL ACTIVITY
Description: A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
Study: NCT02388932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03881319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose acupuncture
Description: Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner Pass(PC6) 、Supreme Rush(LR3) 、Joining Valley(LI4) 、Supreme Stream(KI3) 、Uterus(EX-CA1) 、Leg Three Miles(ST36)
Study: NCT01486134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multipolar Radiofrequency ablation
Description: Percutaneous multipolar radiofrequency ablation.
Study: NCT00745238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: withdrawal of non-invasive ventilation
Description: Four weeks withdrawal of non-invasive ventilation
Study: NCT03565640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capio Slim Device
Description: Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anchorsure Device
Description: Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
Study: NCT00454220

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 33 patients to placebo + 131-I arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRrhTSH
Description: 33 patients to 0.01 mg MRrhTSH + 131-I arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRrhTSH
Description: 33 patients to 0.03 mg MRrhTSH + 131-I arm
Study: NCT00402558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 1.5 mg/kg By Vein Daily x 3 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m\^2 By Vein Over 3 Hours x 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 By Vein Over 30 Minutes x 4 Days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alloreactive NK Infusion
Description: Alloreactive NK infusion from haploidentical donor on Day -8. The alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 x 109/L for 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4 only to participants receiving fourth dose level of NK cells.
Study: NCT01993953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BodyPump
Description: Participants will be offered BP sessions at fitness centers in Oslo/Akershus. They will exercise three times a week. The instructors at all centers have a BP license from Les Mills, and the same program will be conducted at all centers at all times. The project manager has been in contact with Les Mills Scandinavia and has been given permission to use the training concept for research.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personal training
Description: Participants in this group will be offered training with a PT at the Norwegian School of Sports Sciences. They will exercise with their PT three times per week. The training program for this group will be based on the exercises in the BP class, but repetitions will vary between 3-15, and series between 2-4.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training with instructor
Description: Participants in this group will be invited to train on their own, three times a week, at the Norwegian School of Sports Science. Prior to the intervention period they will receive a training manual, instructions of the exercises and advice about progression during the intervention period. They will also have a follow-up with the same instructor after six weeks. The training program for this group will be the same as for group B. The PT's from group B will also serve as training instructors.
Study: NCT03376308

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Score
Description: Four poin scala 0=No Pain~1. mild~2. intermediate~3. severe

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Score
Description: Four poin scala 0=No Pain~1. mild~2. intermediate~3. severe

Intervention type: DIAGNOSTIC_TEST
Intervention: Withdrawal movement score
Description: Withdrawal movements~1. no movement response~2. movement limited to the wrist~3. movement limited to the elbow/shoulder,~4. generalized movement response.

Intervention type: DIAGNOSTIC_TEST
Intervention: Withdrawal movement score
Description: Withdrawal movements~1. no movement response~2. movement limited to the wrist~3. movement limited to the elbow/shoulder,~4. generalized movement response.

Intervention type: DIAGNOSTIC_TEST
Intervention: hemodynamic response
Description: Hemodynamic data were recorded in the patients taken in the operation room. (T0). Hemodynamic values (T1) measured 1 minute after administration of intravenous propofol were recorded. Hemodynamic values (T2) measured 1 minute after administration of intravenous rocuronium were recorded. Hemodynamic values (T3) measured 1 minute after administration of endotracheal intubation were recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: hemodynamic response
Description: Hemodynamic data were recorded in the patients taken in the operation room. (T0). Hemodynamic values (T1) measured 1 minute after administration of intravenous propofol were recorded. Hemodynamic values (T2) measured 1 minute after administration of intravenous rocuronium were recorded. Hemodynamic values (T3) measured 1 minute after administration of endotracheal intubation were recorded.
Study: NCT03316469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: 100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: 100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follicular growth
Description: Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follicular growth
Description: Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.
Study: NCT01774461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
Study: NCT00429936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenretinide
Description: Once daily 30 minutes after the evening meal for 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenretinide
Description: Once daily 30 minutes after the evening meal for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenretinide
Description: Once daily 30 minutes after the evening meal for 24 months
Study: NCT00796952

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: focused attention sessions
Description: Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Valchuff
Description: Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharyngocise
Description: Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
Study: NCT06429228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter removal after surgery
Description: Removal of catheter placed during the procedure in first or second post-surgical days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter removal after surgery
Description: Removal of catheter placed during the procedure in first or second post-surgical days.
Study: NCT00409968

Intervention type: PROCEDURE
Intervention: Tumor Biopsy
Description: A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
Study: NCT02297178

Intervention type: PROCEDURE
Intervention: Cystoscopy only
Description: Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction

Intervention type: PROCEDURE
Intervention: Cystoscopy and Urethral dilatation
Description: Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
Study: NCT02411058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninformed
Description: Users will receive 20x their usual incentives for two weeks, but will either receive no emails informing them about the incentive program.
Study: NCT04261660

Intervention type: OTHER
Intervention: NO intervention
Description: NO INTERVENTION

Intervention type: OTHER
Intervention: NO intervention
Description: NO INTERVENTION

Intervention type: OTHER
Intervention: NO intervention
Description: NO INTERVENTION
Study: NCT04446715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufentanil
Description: Patients will receive sufentanil in spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meperidine
Description: Patients will receive meperidine in spinal anesthesia
Study: NCT02411058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed
Description: Users will receive 20x their usual incentives for two weeks, and they will receive emails informing them about the incentives (one announcement before the incentives begin, and one email every two days reminding them about the overall incentive program). These emails will contain information about the incentives and the purpose of the incentives. The reminder emails sent every two days, however, will include more information about the overall program incentives to maximize the number of participants who learn about the incentive program at some point.
Study: NCT05889364

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-based x-ray analysis and triage (normal/tuberculosis suspected)
Description: All included x-rays will be analysed by the AI-based system. Then results will be compared with opinions of 2 experienced radiologists (they make peer-review of all included images independently of each other).
Study: NCT04446715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Patients will receive 0.5% heavy bupivacaine in spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Patients will receive 0.5% heavy bupivacaine in spinal anesthesia
Study: NCT00477906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-Vax- autologous, hapten-modified melanoma vaccine
Description: Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: M-Vax- autologous, hapten-modified melanoma vaccine
Description: Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
Study: NCT02145078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04570995

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower Oil
Description: Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week
Study: NCT01974505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intubation using optiscope
Description: Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
Study: NCT01286220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dilute bleach baths
Description: Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
Study: NCT02674490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-tDCS (1 mA)
Description: 1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SALT
Description: Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: SALT
Description: Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
Study: NCT00750282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben (BAY94-9172)
Description: Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
Study: NCT03942913

Intervention type: OTHER
Intervention: an observational study
Description: this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
Study: NCT03471390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ProQuaS 2 Intervention
Description: Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
Study: NCT04462497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prototype device
Description: Patients will receive the prototype head and neck support device to be used intraoperatively.
Study: NCT00389181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interventional therapy
Description: All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical management
Description: Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.